Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Antibody (or protein) Drug Conjugates (ADCs)
A unique perspective on the total synthesis of a biomolecule conjugate
We bring together the important knowledge of the science of organic chemistry development for small molecules and the technical expertise of peptide synthesis and post-synthesis modification and conjugation. This is our unique way of developing and manufacturing an Antibody-Drug Conjugate.
Analytical requirements draw from techniques used for both small molecule and large molecules. We have independently developed expertise in both areas and can efficiently develop and validate required methods in-house.
Our small molecule teams are not intimidated by and do not have bias in the handling and purification techniques required for a large molecule. We’ve created an expert team from both the ‘large molecule’ and ‘small molecule’ groups, to implement an ADC project that ensures all challenges are anticipated and met.